Eagle Pharmaceuticals (EGRX) PT Lifted to $75 at Piper Jaffray; Angiomax Another Source of Significant Upside
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE